Sanofi(US:SNY) Globenewswireยท2025-09-23 05:00Core Viewpoint - Sanofi's SAR446268 has received fast track designation from the FDA for treating non-congenital myotonic dystrophy type 1, highlighting the urgency and potential of this gene therapy in addressing an unmet medical need [1][7]. Group 1: Product Development - SAR446268 utilizes a vectorized RNA interference approach to silence DMPK expression, aiming to reduce toxic RNA foci and restore normal muscle function [2]. - The therapy is currently in a first-in-human phase 1-2 study to assess safety, tolerability, and efficacy, with patient enrollment expected to begin in late 2025 [3]. - Sanofi has received orphan designations for SAR446268 in both the US and EU, indicating its potential significance in treating rare diseases [3]. Group 2: Disease Overview - Myotonic dystrophy type 1 (DM1) is a rare genetic disorder affecting approximately 1 in 2,300 people globally, characterized by progressive muscle weakness and various systemic effects [4]. - The condition is caused by mutations in the DMPK gene and has no currently approved treatments, emphasizing the importance of SAR446268 [4][7]. Group 3: Company Profile - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [5].